Top Players and Market Competition in the Parathyroid Hormone Industry

The parathyroid hormone market is poised for significant expansion in the coming years, driven by advances in treatment options and growing healthcare infrastructure. This report delves into the anticipated market growth, key industry players, and emerging trends shaping the future of parathyroid hormone therapies worldwide.

Projected Growth Trajectory of the Parathyroid Hormone Market
The parathyroid hormone market is expected to experience rapid growth, reaching a value of $4.4 billion by 2030. This expansion reflects a robust compound annual growth rate (CAGR) of 11.9%. Several factors contribute to this upward trend, including the development of innovative parathyroid hormone analogues, increased adoption of personalized medicine strategies, expansion of hospitals and specialty clinics, and the integration of digital patient monitoring technologies. Additionally, government and healthcare initiatives targeting hypocalcemia and hypoparathyroidism are playing a crucial role in driving market growth. Key trends during this period include rising cases of hypocalcemia and hypoparathyroidism, wider use of recombinant parathyroid hormone therapies, growth in analogues tailored for personalized treatment, and a focus on post-surgical management supported by vitamin D supplementation.

Download a free sample of the parathyroid hormone market sample:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3427&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Factors Fueling Market Growth for Parathyroid Hormone Treatments
One major driver behind this market's growth is the increasing prevalence of disorders like hypocalcemia and hypoparathyroidism, which necessitate advanced therapeutic interventions. As these conditions become more commonly diagnosed, demand for effective parathyroid hormone-based treatments rises correspondingly.
Moreover, healthcare providers are expanding hospital and clinic-based parathyroid care programs, enhancing patient access and clinical outcomes. Alongside this, evolving digital tools for patient monitoring enable more precise management of therapy, improving overall treatment effectiveness.

Key Players Dominating the Parathyroid Hormone Industry
The parathyroid hormone market features several leading companies that shape its landscape. Notable players include Pfizer Inc., Eli Lilly and Company, Radius Health Inc., Ascendis Pharma, Entera Bio Ltd., Extend Biosciences Inc., Gedeon Richter Plc., Abbott Laboratories, Amgen Inc., Merck & Co. Inc., Novartis AG, F. Hoffmann-La Roche AG, Teva Pharmaceutical Industries Ltd., Alcon Laboratories Inc., Bayer Healthcare, AstraZeneca PLC, Biocon, Dr. Reddy's Laboratories, Glenmark Pharmaceuticals, Jubilant Life Sciences, Lupin Limited, Sun Pharmaceutical Industries, Torrent Pharmaceuticals, Wockhardt, and Cipla Limited.
In a significant move in November 2023, Denmark-based Ascendis Pharma A/S partnered strategically with Japan's Teijin Limited to advance the development and commercialization of novel therapies. This collaboration aims to broaden the availability of Ascendis Pharma's pipeline products in Japan, improving patient care and driving innovation within rare disease and endocrine treatment markets. Teijin Limited is recognized for its commitment to delivering advanced healthcare solutions to meet unmet medical needs.

View the full parathyroid hormone market report:
https://www.thebusinessresearchcompany.com/report/parathyroid-hormones-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Emerging Innovations and Trends Shaping the Parathyroid Hormone Market
A noticeable trend among market leaders is the focus on developing biosimilars and prodrugs of parathyroid hormone to improve treatment options. Prodrugs, which are inactive compounds that convert into active hormones in the body, enable sustained release and more consistent therapeutic effects for calcium regulation and bone health.
For example, in August 2024, Ascendis Pharma A/S announced FDA approval for YORVIPATH (palopegteriparatide), marking the first and only treatment for adult hypoparathyroidism available in the U.S. This once-daily prodrug provides continuous exposure to PTH, benefiting approximately 70,000 to 90,000 patients nationwide. Ascendis Pharma supports patients through its ascendis signature access program (A.S.A.P.), although regular monitoring of serum calcium is required to manage risks of hypercalcemia or hypocalcemia.

Detailed Segmentation of the Global Parathyroid Hormone Market
This report segments the parathyroid hormone market into key categories for better understanding:
1) Disease Type: Hypocalcemia and Hypoparathyroidism
2) Product Type: Recombinant Parathyroid Hormone and Parathyroid Hormone Analogues
3) End-User: Hospitals, Clinics, and Other End-Users
Further breakdowns under disease type include:
• Hypocalcemia: Pseudohypoparathyroidism and Vitamin D Deficiency
• Hypoparathyroidism: Post-Surgical Hypoparathyroidism and Idiopathic Hypoparathyroidism

These classifications provide a comprehensive view of the market's scope, helping stakeholders target specific segments more effectively.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.